X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Reolysin (pelareorep) is an oncolytic reovirus, which can induce a T cells-inflamed phenotype in PDAC. It is being evaluated in combination with atezolizumab in patients with second-line or later unresectable squamous cell carcinoma of the anal canal.
Lead Product(s): Pelareorep,Atezolizumab
Therapeutic Area: Oncology Product Name: Reolysin
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
Reolysin (pelareorep), an intravenously delivered immunotherapeutic agent, which is investigated in combination with atezolizumab in second-line patients with unresectable squamous cell carcinoma of the anal canal.
Lead Product(s): Pelareorep,Atezolizumab
Therapeutic Area: Oncology Product Name: Reolysin
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
The Company intends to use the net proceeds to continue its Reolysin (pelareorep), an intravenously delivered immunotherapeutic agent, clinical programs in metastatic breast cancer and pancreatic cancer.
Lead Product(s): Pelareorep,Retifanlimab
Therapeutic Area: Oncology Product Name: Reolysin
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Leede Jones Gable
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 31, 2023
Details:
Reolysin (pelareorep) treatment resulted in a favorable Risk of Recurrence Score (ROR-S) in 100% of evaluable patients compared to 55% at baseline in a window-of-opportunity study.
Lead Product(s): Pelareorep,Atezolizumab,Trastuzumab
Therapeutic Area: Oncology Product Name: Reolysin
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: SOLTI-Innovative Cancer Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Details:
In IND-213, HR+/HER2- breast cancer patients treated with Reolysin (pelareorep) and paclitaxel showed a statistically significant, near doubling of overall survival compared to those treated with paclitaxel alone.
Lead Product(s): Pelareorep,Paclitaxel,Avelumab
Therapeutic Area: Oncology Product Name: Reolysin
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Adlai Nortye
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
Details:
Results showed Reolysin (pelareorep) treatment led to the activation of NK cells, in patient samples and in vitro, which are known to directly kill cancer cells while stimulating adaptive anti-tumor immunity.
Lead Product(s): Pelareorep,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: Reolysin
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Details:
Results from the trial showed that the combination of Reolysin, Pelareorep-Proteasome Inhibitor was well-tolerated and led to prolonged progression-free survival (PFS) of over three years in a subset of patients.
Lead Product(s): Pelareorep,Dexamethasone,Nivolumab
Therapeutic Area: Oncology Product Name: Reolysin
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022
Details:
These data highlight the potential of pelareorep to benefit patients with pancreatic and other gastrointestinal cancers by reversing immunosuppressive tumor microenvironments that limit the effectiveness of checkpoint inhibitors.
Lead Product(s): Pelareorep,Atezolizumab
Therapeutic Area: Oncology Product Name: Reolysin
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2022
Details:
Enrollment update provided for GOBLET study for Reolysin (pelareorep) an intravenously delivered immunotherapeutic agent in combination with atezolizumab in patients with metastatic pancreatic, metastatic colorectal, and advanced anal cancers.
Lead Product(s): Pelareorep,Atezolizumab
Therapeutic Area: Oncology Product Name: Reolysin
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2022
Details:
BRACELET-1, is ongoing and evaluates pelareorep-paclitaxel combination therapy both with and without a checkpoint inhibitor used in Chinese patients with advanced or metastatic breast cancer.
Lead Product(s): Pelareorep,Paclitaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Adlai Nortye
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
